SCHEMBL4957976

SCHEMBL4957976

CCCCC[C@H](CN(O)C=O)C(=O)NNC(=O)OC(C)(C)C

nearest known ligand 0.62

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 7/20 0.44
MMP12 P39900 1/20 0.41
PDF Q9HBH1 2/20 0.40
APLNR P35414 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4959448 1.00 BMP1 (0.44) BMP1MMP12PDFAPLNRCTSS
SCHEMBL4960111 0.88 BMP1 (0.48) BMP1MMP12PDF
SCHEMBL6024800 0.82 BMP1 (0.47) BMP1MMP12PDF
SCHEMBL5476347 0.81 BMP1 (0.48) BMP1MMP12PDF
SCHEMBL5000934 0.81 BMP1 (0.49) BMP1MMP12
SCHEMBL4960328 0.81 BMP1 (0.42) BMP1MMP12PDF
SCHEMBL6024995 0.80 BMP1 (0.44) BMP1MMP12PDF
SCHEMBL18811603 0.80 APLNR (0.44) APLNRCTSSCTSK
SCHEMBL5006981 0.80 BMP1 (0.42) BMP1MMP12PDF
SCHEMBL4960824 0.80 BMP1 (0.42) BMP1MMP12PDF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363873-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-04-20 EP claimed
US-7019003-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-03-28 US claimed
US-20040087585-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2004-05-06 US claimed
EP-1363873-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-04-20 EP disclosed
US-20080161249-A1 Use of Novel Antibacterial Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-07-03 US disclosed
EP-1827449-A4 THE USE OF NOVEL ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-01-23 EP disclosed
EP-1827449-A2 THE USE OF NOVEL ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-05 EP disclosed
WO-2006055663-A2 THE USE OF NOVEL ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-05-26 WO disclosed
US-7019003-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-03-28 US disclosed
EP-1363873-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-01-04 EP disclosed
US-20040087585-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2004-05-06 US disclosed
EP-1363873-A2 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2003-11-26 EP disclosed
WO-2002070541-A2 PEPTIDE DEFORMYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161249-A1 Use of Novel Antibacterial Compounds MRPL21, NRDC, SPOUT1 BMP1 1513/4885MMP12 332/4885PDF 97/4885
US-20040087585-A1 Peptide deformylase inhibitors PDF, DPEP1, PEPD BMP1 1586/4885MMP12 1038/4885PDF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.